Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Registration Number
- NCT02172482
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
As part of the post-marketing surveillance, information is to be gathered regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 63127
Inclusion Criteria
- Men and women aged at least 40 years presenting with the symptoms of COPD
Exclusion Criteria
- Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Symptoms of COPD Tiotropium bromide Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
- Primary Outcome Measures
Name Time Method Change from baseline in breathlessness when walking/climbing stairs Baseline, after 4 weeks Change from baseline in overall severity of the clinical picture Baseline, after 4 weeks of treatment Occurrence of Adverse Events up to 4 weeks Change from baseline in breathlessness on Physical exercise Baseline, after 4 weeks Change from baseline in breathlessness during housework Baseline, after 4 weeks Change from baseline in breathlessness during everyday activities Baseline, after 4 weeks
- Secondary Outcome Measures
Name Time Method